Karo Pharma completes the acquisition of product portfolio from LEO Pharma
Karo Pharma Aktiebolag (“Karo Pharma”) today announces that the acquisition of the intimate care and dermatology product portfolio from LEO Pharma for 90 MEUR, which was signed and announced by Karo Pharma on 23 December 2019 and approved by relevant competition authorities on 20 February 2020, has been completed.The transaction is expected to contribute positively to Karo Pharma’s market position within intimate care and dermatology and will support the ambitions to expand the European geographical footprint. The acquired portfolio includes four anti-haemorrhoid products: Sheriproct®,